GlaxoSmithKline PLC (GSK) News

GlaxoSmithKline PLC (GSK)

Today's Latest Price: $37.25 USD

0.54 (-1.43%)

Updated Sep 24 11:23am

Add GSK to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 233 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

Filter GSK News Items

GSK News Results

Event/Time Symbol Company News Detail Start End Change POWR Rating
Loading, please wait...

Latest GSK News From Around the Web

Below are the latest news stories about Glaxosmithkline Plc that investors may wish to consider to help them evaluate GSK as an investment opportunity.

Adaptimmune Therapeutics: Mega Profitability

Spend each day trying to be a little wiser than you were when you woke up. Day by day, and at the end of the day if you live long enough like most people, you will get out of life what you deserve. - Charlie Munger (Warren Buffett's partner) In...

BioSci Capital Partners on Seeking Alpha | September 16, 2020

The Zacks Analyst Blog Highlights: Walmart, Oracle, Sanofi, Amazon, GlaxoSmithKline and CVS Health

The Zacks Analyst Blog Highlights: Walmart, Oracle, Sanofi, Amazon, GlaxoSmithKline and CVS Health

Yahoo | September 16, 2020

2 COVID-19 Antibody Stocks to Buy Right Now

Luckily, there are over 300 coronavirus treatment candidates currently in various stages of preclinical and clinical studies. If successful antibody therapeutics could be developed to treat and prevent SARS-CoV-2 infections, they could be game-changers in the fight against the disease that's caused worldwide economic shutdowns and killed almost 200,000 people in the U.S. alone. GlaxoSmithKline (NYSE: GSK) and Regeneron (NASDAQ: REGN) are two companies leading the way in developing prospective antibody treatments for COVID-19.

Yahoo | September 16, 2020

GSK highlights scientific advances across its growing oncology portfolio at ESMO Virtual Congress 2020

LONDON, Sept. 15, 2020 /PRNewswire/ -- GlaxoSmithKline plc will present new data at the upcoming European Society for Medical Oncology (ESMO) Virtual Congress 2020, underscoring its commitment to advancing its growing oncology portfolio, which includes the recent European Commission (EC)…

PR Newswire | September 15, 2020

I reckon GlaxoSmithKline and this growing healthcare company are UK shares to buy

When it comes to UK shares to buy right now, I reckon this company’s recent success and a push for growth make it a strong candidate. The post I reckon GlaxoSmithKline and this growing healthcare company are UK shares to buy appeared first on The Motley Fool UK .

The Motley Fool UK | September 15, 2020

Should You Buy Vir Biotechnology Stock on the Dip?

One of the biggest winners among coronavirus stocks in 2020 has been Vir Biotechnology (NASDAQ: VIR). The company's shares have more than doubled in the span of one year, turning a $10,000 investment from last September into about $22,700 today. Recent controversy surrounding the company's progress with its COVID-19 programs caused the stock to fall more than 40% from its peak in late August.

Yahoo | September 15, 2020

Global Amyloidosis Market Spotlight 2020: GlaxoSmithKline has the Highest Number of Completed Clinical Trials for Amyloidosis, with Five Trials

DUBLIN, Sept. 14, 2020 /PRNewswire/ -- The "Market Spotlight: Amyloidosis" report has been added to's offering. This Market Spotlight report covers the amyloidosis market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst…

PR Newswire | September 14, 2020

Seattle Genetics Pact With Drug Giant Merck Sends SGEN Stock Soaring

Merck and Seattle Genetics announced a new collaboration on a treatment for cancer, a deal that includes Merck buying $1 billion in Seattle Genetics shares, sending SGEN stock soaring.

Yahoo | September 14, 2020

Regeneron's antibody drug added to UK Recovery trial of COVID treatments

The world's largest randomised trial of potential medicines for COVID-19 is to add Regeneron's experimental antiviral antibody cocktail REGN-COV2 to the drugs it is testing in patients hospitalised with the disease. The UK RECOVERY trial, which has been testing a range of potential COVID-19 treatments since it began in April, will compare the effects of adding REGN-COV2 - a lab-manufactured monoclonal antibody - to standard care. "This is the first drug actually designed for this disease," said Martin Landray, a professor of medicine & epidemiology at Oxford University who is co-leading the trial.

Yahoo | September 14, 2020

10 Biggest Pharmaceutical Companies in the World in 2020

In a world dominated by a pandemic, you might wonder how its affecting the 10 biggest pharmaceutical companies in the world in 2020 (click to skip ahead and see the top 3 pharma companies). The pharmaceutical industry is a trillion dollar industry globally, achieving the milestone for the first time in 2014, and the biggest […]

Yahoo | September 13, 2020

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6374 seconds.